Ownership history in DnB Asset Management AS Β· 3 quarters on record
This page tracks every 13F SEC filing in which DnB Asset Management AS reported a position in AbCellera Biologics Inc (ABCL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π DnB Asset Management AS outperformed the S&P 500 by +134.4% annually on this ABCL position. Average cost basis: $4.02. Maximum drawdown during holding period: β0.0%.
π₯ Exceptional β beat the S&P 500 by 134.4% per year on this position.
2 quarters analyzed
Best entry: $2.60 (2024 Q3) Β· Worst: $5.03 (2025 Q3)
π No drawdown exceeding 20% during the holding period β exceptionally stable.
3 adds Β· 0 trims. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.01% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size